IMPACT Therapeutics
英派藥業
- Listing
- HKEX 07630
- Technology platform
- Synthetic lethality
Clinical-stage assets
| Asset | Phase / approval scope | Indication | Source date |
|---|---|---|---|
| Senaparib / IMP4297 | Approved in China since January 2025; European MAA under review | Advanced epithelial ovarian, fallopian tube or primary peritoneal cancer | 2026-07-31 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-07-31 | Pharmanovia | Senaparib / IMP4297 | ≤ EUR 423,500,000 | Approved in China since January 2025; European MAA under review |